Fate Therapeutics, Inc. (NASDAQ:FATE) insider Daniel D. Shoemaker sold 9,482 shares of the business’s stock in a transaction dated Monday, January 11th. The stock was sold at an average price of $114.95, for a total transaction of $1,089,955.90. Following the completion of the transaction, the insider now directly owns 90,336 shares of the company’s stock, valued at $10,384,123.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NASDAQ FATE opened at $113.29 on Thursday. The stock has a market cap of $9.88 billion, a P/E ratio of -61.57 and a beta of 1.84. The firm has a 50 day moving average price of $88.49 and a 200 day moving average price of $51.78. Fate Therapeutics, Inc. has a 52-week low of $16.75 and a 52-week high of $118.79.
Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.39). The firm had revenue of $7.56 million for the quarter, compared to analyst estimates of $7.49 million. Fate Therapeutics had a negative net margin of 810.13% and a negative return on equity of 35.51%. The firm’s revenue for the quarter was up 211.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.40) EPS. On average, analysts forecast that Fate Therapeutics, Inc. will post -1.53 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the company. Epiq Partners LLC boosted its holdings in shares of Fate Therapeutics by 13.6% in the fourth quarter. Epiq Partners LLC now owns 43,468 shares of the biopharmaceutical company’s stock valued at $3,953,000 after buying an additional 5,205 shares during the period. Strs Ohio boosted its holdings in shares of Fate Therapeutics by 92.6% in the third quarter. Strs Ohio now owns 5,200 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 2,500 shares during the period. Sei Investments Co. boosted its holdings in shares of Fate Therapeutics by 28.0% in the third quarter. Sei Investments Co. now owns 20,645 shares of the biopharmaceutical company’s stock valued at $823,000 after buying an additional 4,522 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in shares of Fate Therapeutics in the third quarter valued at approximately $364,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Fate Therapeutics in the third quarter valued at approximately $221,000. Institutional investors own 97.45% of the company’s stock.
About Fate Therapeutics
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors.
Featured Story: How to track put option volume
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.